Keywords
pharmacogenomic
biomarker
How to Cite
Abstract
The development of precision medicine in Africa is contingent upon the establishment of autonomous genomic research capacity. This study characterizes the current landscape of genomic and biomarker trials on the continent using data from ClinicalTrials.gov as of March 2026. A total of 189 genomic trials and 1,149 biomarker trials were identified. Although this represents less than 1% of all registered trials globally, it corresponds to approximately 1.4% of the genomic trial activity observed in the United States. Research capacity was further contextualized by assessing trial density relative to available infrastructure, including an estimated 23 biobanks and 51 projects supported through the H3Africa Initiative.
The findings indicate that, despite incremental gains largely facilitated by collaborative initiatives such as H3Africa, the continent’s capacity for independent pharmacogenomic research remains constrained. This limitation sustains dependence on external institutions for advanced genomic analyses and translational applications. Additionally, the analysis is restricted by its reliance on interventional trial registries, which exclude observational genomic studies and may underestimate overall research activity.
These findings suggest that while genomic research in Africa is expanding, substantial investment in infrastructure, technical expertise, and data governance frameworks is required to support the development of sustainable and sovereign precision medicine systems.
References
[1] N. Mulder et al., “H3Africa: current perspectives,” Pharmgenomics. Pers. Med., vol. Volume 11, pp. 59–66, Apr. 2018, doi: 10.2147/PGPM.S141546.
[2] G. Sirugo, S. M. Williams, and S. A. Tishkoff, “The Missing Diversity in Human Genetic Studies,” Cell, vol. 177, no. 1, pp. 26–31, Mar. 2019, doi: 10.1016/j.cell.2019.02.048.
[3] R. Hardt, S. Jordans, D. Winter, V. Gieselmann, L. Wang-Eckhardt, and M. Eckhardt, “Decreased turnover of the CNS myelin protein Opalin in a mouse model of hereditary spastic paraplegia 35,” Hum. Mol. Genet., vol. 29, no. 22, pp. 3616–3630, Jan. 2021, doi: 10.1093/hmg/ddaa246.
[4] P. Tindana et al., “Community engagement strategies for genomic studies in Africa: a review of the literature,” BMC Med. Ethics, vol. 16, no. 1, p. 24, Dec. 2015, doi: 10.1186/s12910-015-0014-z.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Muruhukye Jacob, Eleanor Sabuka, Anna Nakhabi, Mukisa Paul Brian, Nanono Gloria Margaret, Nabateregga Prossy, Eyong Peter Ebot